Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederic Pouliot

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Cancers|February 13, 2025
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status PatientsNoa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 2, 2020
Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information systemRyan Sun, Rodney H Breau, Ranjeeta Mallick, et al.
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis DatabaseChangsu Lawrence Park, Feras Ayman Moria, Sunita Ghosh, et al.
The Oncologist|August 4, 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell CarcinomaManon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, et al.
BJU International|December 4, 2024
Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?Mustafa Soytas, Alice Dragomir, Ghady Bou-Nehme Sawaya, et al.
Future Oncology (London, England)|June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadirMichael Ong, Christopher Morash, Robert J Hamilton, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 26, 2023
Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional surveySteven M Yip, Christopher Morash, Michael P Kolinsky, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaDavid F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Cancers|February 13, 2025
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status PatientsNoa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|October 2, 2020
Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information systemRyan Sun, Rodney H Breau, Ranjeeta Mallick, et al.
European Urology|July 17, 2022
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell CarcinomaJens Bedke, Brian I Rini, Elizabeth R Plimack, et al.
Current Oncology (Toronto, Ont.)|August 28, 2024
Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis DatabaseChangsu Lawrence Park, Feras Ayman Moria, Sunita Ghosh, et al.
The Oncologist|August 4, 2025
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary Renal Cell CarcinomaManon De Vries-Brilland, Zineb Hamilou, Sunita Ghosh, et al.
BJU International|December 4, 2024
Is there a minimum percentage of sarcomatoid component required to affect outcomes of localised renal cell carcinoma?Mustafa Soytas, Alice Dragomir, Ghady Bou-Nehme Sawaya, et al.
Future Oncology (London, England)|June 19, 2026
Outcomes of a Canadian real-world cohort of metastatic castration-sensitive prostate cancer patients stratified by early PSA nadirMichael Ong, Christopher Morash, Robert J Hamilton, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|July 26, 2023
Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional surveySteven M Yip, Christopher Morash, Michael P Kolinsky, et al.
Pageof 4